1. Search Result
Search Result
Results for "

Meniere’s disease

" in MedChemExpress (MCE) Product Catalog:

9830

Inhibitors & Agonists

122

Screening Libraries

67

Fluorescent Dye

149

Biochemical Assay Reagents

700

Peptides

5

MCE Kits

160

Inhibitory Antibodies

1017

Natural
Products

561

Recombinant Proteins

660

Isotope-Labeled Compounds

167

Antibodies

101

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-132593

    WVE-120101

    Huntingtin Neurological Disease
    Rovanersen (WVE-120101) is an antisense oligonucleotide that specifically targets mutated mRNA copies of the huntington (HTT) gene without affecting healthy mRNA of HTT gene, thereby preventing the production of faulty Huntingtin protein. Rovanersen can be used for huntington’s disease research .
    Rovanersen
  • HY-19490A

    (S)-AQW-051

    nAChR Neurological Disease
    (S)-VQW-765 ((S)-AQW-051) is an orally active, selective and effective α7 nicotinic ACh receptor (nAChR) partial agonist. (S)-VQW-765 has potential applications in cognitive disorders related to neurological diseases, such as Alzheimer's disease or schizophrenia .
    (<em>S</em>)-VQW-765
  • HY-E70226

    CTSS

    Others Cardiovascular Disease Inflammation/Immunology Cancer
    Cathepsin S, human, is a potent cysteine protease that promotes the degradation of damaged or harmful proteins in the endolysosomal pathway. Cathepsin S, human, is involved in multiple pathological processes, including arthritis, cancer, and cardiovascular disease .
    Cathepsin <em>S</em>, human
  • HY-120686

    5-HT Receptor Neurological Disease
    S-14671 is a high-affinity 5-HT1A agonist (pKi=9.3). S-14671 can be used for research on neurological diseases, such as anti-anxiety, anti-depression, etc .
    <em>S</em>-14671
  • HY-124775

    Phosphodiesterase (PDE) Neurological Disease
    (S)-C33 is a potent and selective PDE9 (phosphodiesterase-9) inhibitor, with an IC50 of 11 nM. (S)-C33 can be used for central nervous system diseases and diabetes research .
    (<em>S</em>)-C33
  • HY-109001A

    (1S,2R)-ABT-957

    Proteasome Neurological Disease
    (1S,2R)-Alicapistat ((1S,2R)-ABT-957) is an orally active selective inhibitor of human calpains 1 and 2 for the potential application of Alzheimer's disease (AD) . (1S,2R)-Alicapistat mitigates the metabolic liability of carbonyl reduction and inhibits calpain 1 with an IC50 value of 395 nM .
    (1<em>S</em>,2R)-Alicapistat
  • HY-161331

    Cholinesterase (ChE) Neurological Disease
    S16–1029 is a selective and orally active butyrylcholinesterase (BChE) inhibitor with IC50s of 11.35 nM and 48.1 nM for eqBChE and hBChE, respectively. S16–1029 could cross the blood-brain barrier (BBB) and reach the central nervous system (CNS). S16–1029 can be used for Alzheimer's disease (AD) research .
    <em>S</em>16–1029
  • HY-105545

    (+)-Benzetimide; (S)-(+)-Dexetimide; Dexbenzetimide

    mAChR Neurological Disease
    Dexetimide ((+)-Benzetimide; (S)-(+)-Dexetimide; Dexbenzetimide) is a piperidine anticholinergic and a high-affinity muscarinic receptor antagonist. Dexetimide can be used in studies of parkinson's disease .
    Dexetimide
  • HY-P4521

    MMP Others
    Ac-Pro-Leu-Gly-[(S)-2-mercapto-4-methyl-pentanoyl]-Leu-Gly-OEt is a MMP12 substrate, and can be used to detect MMP12 enzyme activity .
    Ac-Pro-Leu-Gly-[(<em>S</em>)-2-mercapto-4-methyl-pentanoyl]-Leu-Gly-OEt
  • HY-B0311

    (S)-(-)-Carbidopa

    Aryl Hydrocarbon Receptor Neurological Disease Cancer
    Carbidopa ((S)-(-)-Carbidopa), a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa inhibits pancreatic cancer cell and tumor growth .
    Carbidopa
  • HY-139727

    Adrenergic Receptor Cardiovascular Disease
    S(-)-Bisoprolol is a S(-)-enantiomer of Bisoprolol. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .
    <em>S</em>(-)-Bisoprolol
  • HY-139727A

    Adrenergic Receptor Cardiovascular Disease
    S(-)-Bisoprolol fumarate is a S(-)-enantiomer of Bisoprolol fumarate. Bisoprolol fumarate is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .
    <em>S</em>(-)-Bisoprolol fumarate
  • HY-151152

    Cholinesterase (ChE) Neurological Disease
    AChE-IN-24 is a potent AChE inhibitor and can penetrate the BBB. AChE-IN-24 has the mighty inhibitory activity to hAChE with an IC50 value of 0.053 μM. AChE-IN-24 can be used for the research of Alzheimer s disease (AD) .
    AChE-IN-24
  • HY-P99050

    Complement System Cardiovascular Disease Inflammation/Immunology
    Sutimlimab, a first-in-class complement protein component 1, s subcomponent (C1s) inhibitor, can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3 convertase .
    Sutimlimab
  • HY-100617

    (S)-4-Carboxyphenylglycine

    mGluR Neurological Disease
    (S)-4CPG ((S)-4-Carboxyphenylglycine) is a potent mGluR2 agonist. (S)-4CPG reduces hyperalgesia and allodynia associated with sciatic nerve contraction injury in rats. (S)-4CPG can be used in research on neurological diseases .
    (<em>S</em>)-4CPG
  • HY-116541

    ASM

    Bacterial Fungal Infection
    Acibenzolar-S-methyl (ASM) is a plant resistance inducer that mimics pathogen-host interactions and leads to systemic acquired resistance in plants. Acibenzolar-S-methyl helps reduce the use of pesticides and can be used in research to prevent plant diseases .
    Acibenzolar-<em>S</em>-methyl
  • HY-107661A

    (S)ONO-2506; (S)-2-Propyloctanoic acid

    Others Others
    S-(+)-Arundic Acid ((S)ONO-2506) is the S-enantiomer of Arundic Acid. Arundic acid is an astrocyte-modulating agent, has the potential for stroke and Alzheimer’s disease research .
    <em>S</em>-(+)-Arundic Acid
  • HY-17368
    Rivastigmine
    1 Publications Verification

    S-Rivastigmine

    Cholinesterase (ChE) Neurological Disease
    Rivastigmine (S-Rivastigmine) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .
    Rivastigmine
  • HY-156565

    LPL Receptor Inflammation/Immunology
    S1P1 agonist 6 (Compound I) is a S1P1 agonist that reduces autoimmune ability by blocking the transportation of lymphocytes. S1P1 agonist 6 can be used as an immunosuppressive agent in the study of various autoimmune diseases research .
    <em>S</em>1P1 agonist 6
  • HY-15382
    FTY720 (S)-Phosphate
    1 Publications Verification

    (S)-FTY720P; (S)-FTY720 phosphate

    LPL Receptor Inflammation/Immunology
    FTY720 (S)-Phosphate is an agonist of S1P receptor 1 (S1PR1), used in the research of acute inflammatory diseases such as acute lung injury.
    FTY720 (<em>S</em>)-Phosphate
  • HY-121765

    N,S-Diacetyl-L-cysteine

    Endogenous Metabolite Metabolic Disease
    Dacisteine (N,S-Diacetyl-L-cysteine) is a cysteine derivative and displays a less New Delhi metallo-beta-lactamase-1 (NDM-1) inhibitor with an IC50 value of 1000 μM . Dacisteine can be used for the treatment of cardiovascular and cerebrovascular diseases caused by platelet aggregation .
    Dacisteine
  • HY-137451A

    (E/Z)-S-600918

    P2X Receptor Inflammation/Immunology
    (E/Z)-Sivopixant ((E/Z)-S-600918) is a potent P2X3 receptor antagonist with an IC50 of 4 nM. (E/Z)-Sivopixant can be used for respiratory diseases research .
    (E/Z)-Sivopixant
  • HY-P1438

    Neuropeptide Y Receptor Neurological Disease
    Neuropeptide S (Rat) is an endogenous ligand of a previously orphan G-protein-coupled receptor now named NPS receptor. Neuropeptide S (Rat) can be used for the research of nervous system disease .
    Neuropeptide <em>S</em>(Rat)
  • HY-110001

    5-HT Receptor Neurological Disease
    (S)-WAY 100135 dihydrochloride is a highly selective and potent antagonist of 5-HT 1A (IC50=33.9 nM). (S)-WAY 100135 dihydrochloride has anxiolytic activity in animal models .
    (<em>S</em>)-WAY 100135 dihydrochloride
  • HY-134661

    GPR6 Neurological Disease
    (S)-CVN424 is a potent G-Protein-Coupled Receptor 6 (GPR6) modulator. (S)-CVN424 has the potential for a variety of neurological and psychiatric disorders research, including Parkinson's disease .
    (<em>S</em>)-CVN424
  • HY-156601A

    5-HT Receptor Neurological Disease
    (S)-Bexcaserin (compound 2) is a 5-HT2C receptor agonist with potential for studying obesity and psychiatric-related diseases .
    (<em>S</em>)-Bexicaserin
  • HY-N0707

    1-Methyl-L-tryptophan; (S)-NLG-8189

    Indoleamine 2,3-Dioxygenase (IDO) Neurological Disease Cancer
    (S)-Indoximod (1-Methyl-L-tryptophan) is an inhibitor of indoleamine 2,3-dioxygenase (IDO) (Ki: 19 μM). (S)-Indoximod can be used for the research of cancer and neurological disease .
    (<em>S</em>)-Indoximod
  • HY-114415

    Parasite Infection
    AWZ1066S is a highly potent, specific and orally active anti-Wolbachia agent with EC50 value of 121 nM. AWZ1066S also is a weak CYP2C9 inhibitor and a weak CYP3A4 inducer with IC50 values of 9.7 μM and 37 uM, respectively. AWZ1066S can be used for the research of tropical diseases such as Onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) .
    AWZ1066<em>S</em>
  • HY-143864

    LPL Receptor Inflammation/Immunology
    S1PR1 agonist 1 is a potent agonist of S1PR1. Sphingosine-1-phosphate (S1P) is a cell membrane-derived lysophospholipid signalling molecule that exerts its physiological functions mainly by stimulating some members of the G protein-coupled receptor family. S1PR1 agonist 1 has the potential for the research of autoimmune diseases (extracted from patent WO2021175223A1, compound 22) .
    <em>S</em>1PR1 agonist 1
  • HY-143865

    LPL Receptor Inflammation/Immunology
    S1PR1 agonist 2 is a potent agonist of S1PR1. Sphingosine-1-phosphate (S1P) is a cell membrane-derived lysophospholipid signalling molecule that exerts its physiological functions mainly by stimulating some members of the G protein-coupled receptor family. S1PR1 agonist 2 has the potential for the research of autoimmune diseases (extracted from patent WO2021175225A1, compound 1) .
    <em>S</em>1PR1 agonist 2
  • HY-B0617

    S-Adenosyl methionine; Ademetionine; AdoMet

    Endogenous Metabolite Apoptosis Neurological Disease Inflammation/Immunology Cancer
    S-Adenosyl-L-methionine (S-Adenosyl methionine) is an orally active methyl group donor. S-Adenosyl-L-methionine is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine has the potential for, cancer, liver disease and osteoarthritis research .
    <em>S</em>-Adenosyl-L-methionine
  • HY-107518

    (R,S)-3,4-DCPG

    iGluR Neurological Disease
    (R,S)-3,4-Dicarboxyphenylglycine ((RS)-3,4-DCPG) is an AMPA receptor antagonist. (R,S)-3,4-Dicarboxyphenylglycine antagonizes AMPA-mediated depolarization of motor neurons in neonatal rats. (R,S)-3,4-Dicarboxyphenylglycine can be used in the study of neurological diseases .
    (R,<em>S</em>)-3,4-Dicarboxyphenylglycine
  • HY-109046
    Tulrampator
    1 Publications Verification

    CX-1632; S-47445

    iGluR mTOR Neurological Disease
    Tulrampator (S-47445) is an orally active selective AMPA receptor modulator. Tulrampator possesses procognitive, enhancing synaptic plasticity, anti-depressant-anxiolytic-like, procognitive and potential neuroprotective properties. Tulrampator can be used for research of alzheimer’s disease and in major depressive disorder .
    Tulrampator
  • HY-15382A

    LPL Receptor Inflammation/Immunology
    FTY720 (S)-Phosphate is an agonist of S1P receptor 1 (S1PR1), used in the research of acute inflammatory diseases such as acute lung injury.
    (<em>S</em>)-FTY720-phosphonate
  • HY-107660

    Sirtuin Neurological Disease
    SIRT2-IN-8 is a potent SIRT2 inhibitor. SIRT2-IN-8 can be used for Huntington’s and Parkinson’s diseases research .
    SIRT2-IN-8
  • HY-W017770

    Ademetionine disulfate tosylate; S-Adenosyl methionine disulfate tosylate; AdoMet disulfate tosylate

    Endogenous Metabolite Apoptosis Neurological Disease Cancer
    S-Adenosyl-L-methionine disulfate tosylate is the disulfate tosylate form of S-Adenosyl-L-methionine (HY-B0617). S-Adenosyl-L-methionine is an orally active methyl group donor. S-Adenosyl-L-methionine is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine has the potential for, cancer, liver disease and osteoarthritis research .
    <em>S</em>-Adenosyl-L-methionine disulfate tosylate
  • HY-115688A
    (S)-TXNIP-IN-1
    1 Publications Verification

    Others Others
    (S)-TXNIP-IN-1 is the less active S-enantiomer of TXNIP-IN-1 (HY-115688). TXNIP-IN-1 is a TXNIP-TRX complex inhibitor which can be used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease
    (<em>S</em>)-TXNIP-IN-1
  • HY-B0617A

    S-Adenosyl methionine tosylate; Ademetionine tosylate; AdoMet tosylate

    Endogenous Metabolite Apoptosis Neurological Disease Inflammation/Immunology Cancer
    S-Adenosyl-L-methionine tosylate is produced endogenously from methionine and ATP by action of the enzyme methionine adenosyltransferase and is an important orally active methyl group donor. S-Adenosyl-L-methionine tosylate is a dietary supplement with potent antidepressant and analgesic effects, and has the potential for liver disease and osteoarthritis research .
    <em>S</em>-Adenosyl-L-methionine tosylate
  • HY-148867

    2-(Fluoromethoxy)-4'-(S-methylsulfonimidoyl)-1,1'-biphenyl

    Dopamine Receptor Neurological Disease
    UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD) .
    UCM-1306
  • HY-141411A

    (S)-MRI-1867

    Cannabinoid Receptor NO Synthase Metabolic Disease
    Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD) .
    Zevaquenabant
  • HY-139331

    Proteasome Neurological Disease Inflammation/Immunology Cancer
    20S Proteasome-IN-1 is a 26S proteasome inhibitor extracted from patent WO2006128196A2 compound 2. 20S Proteasome-IN-1 has the potential for cancer, immune-related disorders, inflammation, ischemic conditions, neurodegenerative disorders and other diseases research .
    20<em>S</em> Proteasome-IN-1
  • HY-15344A

    (S,S)-Ketone Ester

    Others Neurological Disease
    (S,S)-BD-AcAc 2 ((S,S)-Ketone Ester) is a (S,S)-enantiomer of BD-AcAc 2. BD-AcAc 2 elevates the AcAc and acetone levels, thereby produces sustained ketosis and significantly delays central nervous system oxygen toxicity (CNS-OT) seizures .
    (<em>S</em>,<em>S</em>)-BD-AcAc 2
  • HY-157400

    Monoamine Oxidase Neurological Disease
    hMAO-B-IN-7 (compound 11n) is a potent and blood–brain barrier (BBB) penetrable inhibitor of human monoamine oxidase-B (hMAO-B), with the IC50 value of 0.79±0.05 μM. hMAO-B-IN-7 can be used for Alzheimer’s disease (AD) and Parkinson’s disease (PD) research .
    hMAO-B-IN-7
  • HY-U00366

    LPL Receptor Inflammation/Immunology
    S1PR-MO-1 is the modulator of sphingosine-1-phosphate receptor, used for research of hyperproliferative, inflammatory diseases.
    <em>S</em>1PR1-MO-1
  • HY-17503S2

    Isotope-Labeled Compounds Adrenergic Receptor Cardiovascular Disease Endocrinology
    (S)-Metoprolol-d7 is the deuterium labeled Metoprolol. Metoprolol (Toprol) is a selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension[1][2].
    (<em>S</em>)-Metoprolol-d7
  • HY-141845

    LPL Receptor Others
    S1P2 antagonist 1 is an orally bioavailable S1P2 antagonist against fibrotic diseases.
    <em>S</em>1P2 antagonist 1
  • HY-145519

    Fluorescent Dye Neurological Disease
    Mu-6S-Palm-β-Glc is a fluorogenic substrate for palmitoyl-protein thioesterase (PPT). Mu-6S-Palm-β-Glc can be used for the research of neuronal ceroid lipofuscin disease in infants .
    Mu-6<em>S</em>-Palm-β-Glc
  • HY-17507E

    Proton Pump Bacterial Infection
    S-Pantoprazole (sodium trihydrate) is related to Pantoprazole (HY-17507) that plays an important roles in gastric acid secretion disorder-related diseases, or as proton pump inhibitor .
    <em>S</em>-Pantoprazole sodium trihydrate
  • HY-147976

    Glucosidase Neurological Disease Metabolic Disease
    Glucocerebrosidase-IN-1 (compound 11a) is a potent and selective GCase (glucocerebrosidase) inhibitor, with an IC50 of 29.3 μM and a Ki of 18.5 μM. Glucocerebrosidase-IN-1 can be used for the research of Gaucher disease (GD) and Parkinson’s disease (PD) .
    Glucocerebrosidase-IN-1
  • HY-150602

    Proteasome Neurological Disease
    20S Proteasome activator 1 is a potent 20S proteasome activator with EC200 values of 0.3 μM, 0.7 μM and 1.8 μM for trypsin-like site, chymotrypsin-like site and caspase-like site. 20S Proteasome activator 1 translates well in a cellular system, preventing the accumulation of the pathogenic A53T mutant of α-synuclein. 20S Proteasome activator 1 can be used for researching neurodegenerative diseases .
    20<em>S</em> Proteasome activator 1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: